Show simple item record

dc.creatorMonteiro P. Palma, Lilian
dc.creatorSridharan, Meera
dc.creatorSethi, Sanjeev
dc.date.accessioned2020-11-04T20:01:03Z
dc.date.available2020-11-04T20:01:03Z
dc.date.created2020
dc.identifier.issn2468-0249spa
dc.identifier.otherhttps://doi.org/10.1016/j.ekir.2020.10.009spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/15360
dc.description.abstractThrombotic microangiopathy (TMA) is a condition characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) with varying degrees of organ damage in the setting of normal International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPTT). Complement has been implicated in the etiology of TMA, which are classified as Primary TMA - when genetic and acquired defects in complement proteins are the primary drivers of TMA (complement-mediated TMA or atypical hemolytic uremic syndrome, aHUS) or Secondary TMA, when complement activation occurs in the context of other disease processes, such as infection, malignant hypertension, autoimmune disease, malignancy, transplantation, pregnancy and drugs. It is important to recognize that this classification is not absolute as genetic variants in complement genes have been identified in patients with secondary TMA, and distinguishing complement/genetic-mediated TMA from secondary causes of TMA can be challenging and lead to potentially harmful delays in treatment. In this review, we focus on data supporting the involvement of complement in aHUS and in secondary forms of TMA associated with malignant hypertension, drugs, autoimmune diseases, pregnancy and infections. In aHUS, genetic variants in complement genes are found in up to 60% of patients, whereas in the secondary forms the finding of genetic defects is variable, ranging from almost 60% in TMA associated with malignant hypertension to less than 10% in drug-induced TMA. Based on these findings, a new approach to management of TMA is proposed.spa
dc.format.extent32 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherKidney International Reportsspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectThrombotic microangiopathyspa
dc.titleComplement in secondary thrombotic microangiopathyspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.ekir.2020.10.009spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record